Search clinical trials for: SY-008

Total 2040 results

Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

Multiple Ascending Doses of SY-008 in Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

Single Ascending Oral Doses of SY-008 in Healthy Subjects

Diabetes

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

The Efficacy and Safety of Different Doses of SY-004 in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Suspended

SY007 in Patients With Acute Ischemic Stroke

Acute Ischemic Stroke

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

Multiple Ascending Doses of SY-009 in Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

Single Ascending Oral Doses of SY-009 in Healthy Subjects

Diabetes

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

Single-dose Incremental Intravenous Injection of SY-007 in Healthy Subjects

Cerebral Apoplexy

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Not yet recruiting

The Efficacy and Safety of Different Doses of SY-009 in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

Single-dose/Multiple-doses Incremental Intravenous Injection of SY-005 （Recombinant Human Annexin A5）in Healthy Subjects

Sepsis

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Recruiting

SY-005 （Recombinant Human Annexin A5）in Patients With Sepsis

Sepsis

China
University of Pennsylvania

Terminated

Penn Microbiome Therapy for Recurrent Clostridium Difficile Infection

Recurrent Clostridium Difficile Infection

United States
Revibe Technologies

Completed

Assessing a Wearable Digital Therapy for Youth With ADHD

ADHD

United States
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

A Food-drug Interaction Study of SY-004 in Healthy Subjects

Type 2 Diabetes

China
Shouyao Holdings (Beijing) Co. LTD

Recruiting

Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor

Non-Small Cell Lung Cancer | Solid Tumor | Medullary Thyroid Cancer

China
Shouyao Holdings (Beijing) Co. LTD

Recruiting

Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC

Non-Small Cell Lung Cancer

China
Shouyao Holdings (Beijing) Co. LTD

Recruiting

A Study of SY-5933 in Patients With Advanced Solid Tumors Harboring the KRAS p.G12C Mutation

Advanced Solid Tumor

China
Shouyao Holdings (Beijing) Co. LTD

Recruiting

A First-in-Human, Phase 1 Study of SY-4798 in Patients With Advanced Solid Tumor

Advanced Solid Tumor

China
Shouyao Holdings (Beijing) Co. LTD

Recruiting

A Phase I Study of SY-4835 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
University of Manitoba
Canadian Institutes of Health Research (CIHR); Canadian Cancer Society (CCS); The Canadian Collaborative for Childhood Cannabinoid Therapeutics

Not yet recruiting

CANnabinoids in Pediatric ONCology (CAN-PONC)

Cancer | Childhood Cancer
EyeGene Inc.
Novotech (Australia) Pty Limited

Completed

Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-HZ in Healthy Adult Volunteers

Prevention of Herpes Zoster (HZ)

Australia
University of Pennsylvania

Terminated

Penn Microbiome Therapy (PMT) for Severe-Clostridium Difficile Infection (CDI)

Severe Clostridium Difficile Infection | Severe-Complicated/Fulminant Clostridium Difficile Infection

United States
Shouyao Holdings (Beijing) Co. LTD

Not yet recruiting

A Study to Evaluate the Food Effects on Pharmacokinetics of SY-5007 Tablets in Healthy Subjects

Health Subjects

China
Seinda Pharmaceutical Guangzhou Corporation

Completed

Study of SY-201 Ophthalmic Solution in Subjects With Dry Eye Disease

Dry Eye Disease

United States
Shouyao Holdings (Beijing) Co. LTD

Not yet recruiting

A Study to Evaluate the Mass Balance of [14C] SY-5007 in Healthy Adult Male Subjects in China

Healthy Subjects

China
Yabao Pharmaceutical Group

Completed

Multiple Ascending Doses of Globalagliatin Hydrochloride in Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus | Hyperglycaemia (Diabetic)

China
Yabao Pharmaceutical Group

Completed

The Assessment of Single-Dose Safety,Tolerability, Pharmacokinetics and Pharmacodynamic of Globalagliatin Hydrochloride

Healthy Volunteers | Hyperglycaemia (Diabetic)

China
Shouyao Holdings (Beijing) Co. LTD

Recruiting

Phase I/II Study of SY-3505 in Patients With ALK-positive Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Lawson Health Research Institute
London Health Sciences Foundation; Ontario Ministry of Colleges and Universities

Recruiting

Annexin A5 in Patients With Severe COVID-19 Disease (AX-COVID)

Coronavirus Infection | Sepsis

Canada
Hvivo
Prep Biopharm Limited

Completed

Study Examining PrEP-001 in Subjects With Asthma

Asthma
Syros Pharmaceuticals

Terminated

A Study of SY-1365 in Adult Patients With Advanced Solid Tumors

Breast Cancer | Ovarian Cancer | Advanced Solid Tumors

United States, Canada, France
PMG Pharm Co., Ltd

Completed

Study to Compare the Safety and Pharmacokinetics of PK101 With Coadministration of the Two Separate Drugs

Arthritis

Korea, Republic of
DermBiont, Inc.

Suspended

A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Onychomycosis

Onychomycosis

United States
EGEN, Inc.

Terminated

Safety Study of phIL-12-005/PPC to Treat Recurrent Ovarian Cancer

Ovarian Neoplasms

United States
Shouyao Holdings (Beijing) Co. LTD

Recruiting

Phase II Study of SY-3505 in Patients With ALK-positive NSCLC Who Have Failed Prior Second-Generation ALK TKI

Non-small-cell Lung Carcinoma

China
Kukje Pharma

Completed

[KSR-001-P01]Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristic of KSR-001

Dry Eye Syndromes

Korea, Republic of
Sun Pharma Advanced Research Company Limited

Completed

Study of Doxorubicin in Patients With Metastatic Breast Cancer/Advanced Ovarian Cancer

Breast Cancer and Ovarian Cancer
DermBiont, Inc.

Active, not recruiting

A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Tinea Pedis

Tinea Pedis

United States
Pieris Pharmaceuticals GmbH
FGK Clinical Research GmbH; Nuvisan Pharma Services; EUROCALIN Consortium

Completed

First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PRS-080

Healthy

Germany
Shouyao Holdings (Beijing) Co. LTD

Recruiting

A Study of SY-3505 in Patients With Advanced LTK Fusion-Positive Solid Tumors

Advanced Solid Tumor

China
Hvivo
Prep Biopharm Limited

Completed

Study Examining PrEP-001 in Healthy Subjects

Influenza A H3N2

United Kingdom
Pfizer

Completed

A Study to Assess the Safety and Tolerability of Different Doses of PF-05402536 and PF-06413367 in Healthy Adult Smokers.

Smoking | Vaccines

Canada
M.D. Anderson Cancer Center

Active, not recruiting

iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

Pancreatic Ductal Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | KRAS NP_004976.2:p.G12D

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma

Diffuse Large B-Cell Lymphoma | Recurrent Mantle Cell Lymphoma | Mantle Cell Lymphoma | B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Transformed Non-Hodgkin Lymphoma

United States
Taejoon Pharmaceutical Co., Ltd.

Completed

A Prospective, Randomized, Single-blinded (Evaluator), Parallel, Multi-center, Phase 3 Trial in Bowel Preparation for Colonoscopy

Bowel Preparation

Korea, Republic of
M.D. Anderson Cancer Center
National Cancer Institute (NCI); ADC Therapeutics S.A.

Recruiting

ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Philadelphia Chromosome Positive | Blasts 5 Percent or More of Bone Marrow Nucleated Cells | CD22 Positive

United States
Pieris Pharmaceuticals GmbH
FGK Clinical Research GmbH

Unknown

Phase Ib Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients

Anemia of Chronic Kidney Disease

Germany
Pieris Pharmaceuticals GmbH
FGK Clinical Research GmbH

Completed

Phase 2a Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients

Anemia of Chronic Kidney Disease

Czechia, Germany
Antengene Therapeutics Limited

Terminated

Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular Carcinoma (HCC) Subjects

Hepatocellular Carcinoma

Korea, Republic of, Taiwan, China
Exicure, Inc.

Completed

A Study of AST-008 in Healthy Subjects

Healthy Volunteer Study

United Kingdom
Morphotek

Completed

A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers

Pancreatic Cancer | Ovarian Cancer | Mesothelioma | Non-small Cell Lung Cancer

United States

Search clinical trials for: SY-008

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Papua New Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations